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Abstract
Background: The non-invasive assessment of airway inflammation is potentially advantageous in asthma 
management. Exhaled carbon monoxide (eCO) measurement is cheap and has been proposed to reflect airway 
inflammation and oxidative stress but current data are conflicting. The purpose of this meta-analysis is to determine 
whether eCO is elevated in asthmatics, is regulated by steroid treatment and reflects disease severity and control.
Methods: A systematic search for English language articles published between 1997 and 2009 was performed using 
Medline, Embase and Cochrane databases. Observational studies comparing eCO in non-smoking asthmatics and 
healthy subjects or asthmatics before and after steroid treatment were included. Data were independently extracted 
by two investigators and analyzed to generate weighted mean differences using either a fixed or random effects meta-
analysis depending upon the degree of heterogeneity.
Results: 18 studies were included in the meta-analysis. The eCO level was significantly higher in asthmatics as 
compared to healthy subjects and in intermittent asthma as compared to persistent asthma. However, eCO could not 
distinguish between steroid-treated asthmatics and steroid-free patients nor separate controlled and partly-controlled 
asthma from uncontrolled asthma in cross-sectional studies. In contrast, eCO was significantly reduced following a 
course of corticosteroid treatment.
Conclusions: eCO is elevated in asthmatics but levels only partially reflect disease severity and control. eCO might be a 
potentially useful non-invasive biomarker of airway inflammation and oxidative stress in nonsmoking asthmatics.
Background
Asthma is a chronic inflammatory disorder of the air-
ways, associated with airway hyperresponsiveness (AHR)
that leads to recurrent episodes of wheezing, breathless-
ness, chest tightness, and coughing, particular at night or
in the early morning [1]. The assessment of airway
inflammation is likely to play an important role in the
future management of asthma. However, the "gold stan-
dard" for assessment of airway inflammation, bronchial
biopsy, is invasive and too expensive to perform on a reg-
ular basis. Hence, much attention is paid to the non-inva-
sive measurement of airway inflammation, such as
induced sputum and of surrogates such as exhaled nitric
oxide (eNO).
The level of eNO is elevated in asthmatics, even when
asymptomatic [2-4], and shows a good response to corti-
costeroids [5,6]. However, the measurement of eNO is
expensive, limiting its use in primary care and most spe-
cialist clinics.
Some studies have reported that exhaled carbon mon-
oxide (eCO), which is used as an indicator of smoking [7],
is significantly increased in asthmatics not treated with
corticosteroids [8,9]. CO in the body is mainly derived
from the degradation of hemoglobin by the enzyme heme
oxygenase (HO) [10]. It has been found that the expres-
sion of the inducible isoform, HO-1, is increased in alveo-
lar macrophages in asthmatics in association with
increased exhaled CO [9]. These findings suggested that
eCO may be a candidate of non-invasive biomarker of air-
way inflammation.
However, several studies have failed to replicate these
early results [11,12]. We therefore performed a meta-
analysis of the published evidence to determine whether
eCO is increased in asthmatic adults and children, and
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enced by corticosteroids.
Methods
A comprehensive literature search from 1997 to 2009 in
English language was performed in Medline (using
PubMed as the search engine), Embase and Cochrane
databases. The search terms were 'exhaled CO', 'expired
CO', 'carbon monoxide', 'asthma', 'bronchial spasm',
'bronchoconstriction', 'bronchial hyperreactivity', 'airway
inflammation', 'wheeze' and 'wheezing'. (Additional file 1)
A priori inclusion criteria was: 1) observational studies;
2) comparing eCO levels between adults or children with
an established diagnosis of asthma and healthy control
subjects or comparing eCO levels in the same asthmatic
population before and after steroid treatment; 3) both
asthmatic patients and healthy subjects were nonsmok-
ers, since smoking status could significantly affect eCO
levels [7]. Exclusion criteria included: 1) asthmatic
patients with systemic diseases, such as diabetes, sepsis
[13,14] and 2) studies without healthy subjects as the con-
trol group.
A systematic search including a title screen, abstract
review, and full text article review. Each study was evalu-
ated independently by two investigators (JZ and YS). Any
disagreements about adjudications were resolved
through the third party (XY). For each eligible study, we
extracted data including number of participants (n), age,
gender, clinical feature, treatment, method measuring
eCO, and the mean value (mean), standard deviation
(SD), 95% confidence interval (CI), or standard error of
mean (SEM) of exhaled CO. SEM or 95%CI was trans-
formed to SD, using standard statistical conversions.
Review Manager (Version 5, The Cochrane Collabora-
tion) was used to generate the weighted mean differences
(WMD) of eCO between asthmatics and healthy subjects.
I2 statistic was tested for heterogeneity. We used a fixed
effects model when I2 was equal or less than 50%, and a
random effects model when I2 was greater than 50%.
Meta-regression analysis on the time of publication was
performed by STATA (Version 9.2, STATA Corporation,
College Station). Subgroup analysis was performed,
according to: 1) whether the study group consisted of
adult or children, 2) whether the participants were
treated with corticosteroids (systemic or inhaled), 3) the
clinical severity of asthma. Publication bias was evaluated
through visual inspection of funnel plots, the Begg's test
[15] and the Egger's Asymmetry test [16], calculating by
STATA. Publication bias may be present if P value is less
than 0.05.
Results
Figure 1 shows the results of the search for articles. Of the
total 644 articles, 184 duplicates and 349 irrelevant stud-
ies were excluded after screening the titles. A further 82
articles failed to meet the inclusion criteria after abstract
review. Among the remaining 29 articles, 6 studies did
not have healthy control groups and 5 studies did not
provide sufficient eCO data such as mean value, SD,
95%CI or SEM. We subsequently tried to contact the
authors by email to obtain further information without
success. Finally, 18 articles were included in our meta-
analysis [17-34]. 4 studies directly provided SD of eCO, 2
studies used 95%CI and the remaining studies provided
SEM. As no unequal variances were mentioned in these
studies, the classical t-test was used to transform 95%CI
into SD. The characteristics of the 18 studies were listed
in the Additional file 2, 3. There were no evidence of pub-
lication bias (Begg's test: P = 0.843; Egger's Asymmetry
test: P = 0.211; Figure 2 shows the Funnel plot). The het-
erogeneity between different studies is significant (I2 =
75%), therefore, we performed a meta-regression analysis
on the time of publication. The τ2 estimate is 0.3782,
which means the time of publication could only partly
explain the heterogeneity.
1. Overall eCO levels in asthmatics and healthy subjects
Data was pooled from 15 studies irrespective of the age of
the participants, the severity of disease or treatment. The
overall WMD of eCO between asthmatics and healthy
subjects was 1.25 ppm (95% CI 0.92 to 1.58; I2 = 75%;
Random effects model). Asthmatic patients showed sig-
nificantly higher eCO levels as compared to healthy sub-
jects. (Figure 3)
2. eCO levels in childhood and adult asthma
There were 7 articles focused on childhood asthma and 7
on adult asthma. The remaining article [31] studied a
population above 10 years old and, therefore, could not
be included as either childhood or adult asthma. The
WMD of eCO between asthmatic children and healthy
children was 0.95 ppm (95% CI 0.65 to 1.24; I2 = 59%;
Random effects model). And the WMD of eCO between
asthmatic adults and healthy adults was 1.49 ppm (95%
CI 0.84 to 2.14; I2 = 73%; Random effects model). Both
asthmatic children and asthmatic adults showed signifi-
cant higher eCO levels compared to healthy children and
healthy adults respectively. (Figure 4)
3. eCO levels in steroid-free and steroid-treated asthmatics
13 articles mentioned steroid-free asthmatics (defined as
either steroid naïve or not receiving regular inhaled or
systemic corticosteroids and treated by on-demand β2-
agonist), and 8 articles mentioned steroid-treated asth-
matics (defined as current use of inhaled or systemic cor-
ticosteroids irrespective of β2-agonist or montelukast
use). The WMD of eCO was 1.39 ppm (95%CI 0.82 to
1.95; I2 = 91%; Random effects model) between steroid-
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(95%CI 0.35 to 1.23; I2 = 84%; Random effects model)
between steroid-treated asthmatics and healthy subjects.
Both steroid-free and steroid-treated asthmatics had sig-
nificantly higher eCO levels than healthy subjects. Ste-
roid-treated asthmatic patients had lower eCO levels
compared to steroid-free asthmatic patients (0.79 ppm vs
1.39 ppm) but this failed to reach statistical significance.
(Figure 5)
4. eCO levels in different asthma severities
According to the GINA [1] criteria, there are 4 categories
of disease severity: intermittent, mild persistent, moder-
ate persistent and severe persistent asthma. However, due
Figure 1 Results of the systematic literature search.
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could not differentiate mild persistent asthma from mod-
erate persistent asthma. Therefore, we separated the sub-
jects into three groups: intermittent asthma (4 articles),
mild + moderate persistent asthma (8 articles) and severe
persistent asthma (2 articles). The WMD of eCO was 0.31
ppm (95%CI 0.16 to 0.46; I2 = 11%; Fixed effects model)
between intermittent asthmatics and healthy subjects
(Figure 6), 0.84 ppm (95%CI 0.48 to 1.20; I2 = 62%; Ran-
dom effects model) between mild + moderate persistent
asthmatics and healthy subjects, and 2.20 ppm (95% CI
0.29 to 4.10; I2 = 68%; Random effects model) between
severe persistent asthmatics and healthy subjects (Figure
7). The eCO levels were higher across all asthma severi-
ties as compared to healthy subjects. Furthermore, both
mild + moderate persistent and severe persistent asth-
matics showed significantly higher eCO levels than inter-
mittent asthmatics. However, the eCO level of mild +
moderate persistent asthma did not differ significantly
from that of severe persistent asthma.
5. eCO levels in different asthma control states
We attempted to classify asthma control status into 3 cat-
egories: controlled, partly controlled and uncontrolled
[1]. However, some studies did not provide enough infor-
mation to distinguish between controlled and partly con-
trolled disease. Thus, we divided subjects into 2 groups:
controlled + partly controlled group (6 articles) and
uncontrolled group (3 articles). The WMD of eCO was
1.20 ppm (95%CI 0.39 to 2.01; I2 = 91%; Random effects
model) between controlled + partly controlled asthmatics
and healthy subjects, and 2.12 ppm (95%CI 0.56 to 3.68; I2
= 95%; Random effects model) between uncontrolled
asthmatics and healthy subjects. Both controlled + partly
controlled asthma and uncontrolled asthma showed sig-
nificantly higher eCO levels as compared to healthy sub-
jects. There was no statistical difference in eCO levels
between controlled + partly controlled and uncontrolled
asthma. (Figure 8)
6. eCO levels in asthmatics before and after steroid 
treatment
There were 7 articles focusing on the influence of corti-
costeroid treatment on eCO, including 4 studies with
inhaled corticosteroids, 2 studies with oral glucocorti-
coids and the remaining study with both inhaled and oral
corticosteroids (the details of the studies are shown in
Figure 2 Begg's funnel Plot.
Figure 3 Overall eCO levels in asthmatics. The WMD of eCO levels between asthmatics and healthy subjects is 1.25 ppm (95%CI: 0.92 to 1.58) using 
the random effects model. Test for heterogeneity I2 = 75%. SD: standard deviation; IV: inverse variance; CI: confidence interval; WMD: weighted mean 
difference; eCO: exhaled carbon monoxide.
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and after steroid treatment was 1.98 ppm (95%CI 0.53 to
3.43; I2 = 94%; Random effects model) indicating that
eCO was significantly reduced by steroid treatment. (Fig-
ure 9)
Discussion
This meta-analysis based on 15 studies in 632 asthmatics
and 734 healthy subjects demonstrates that eCO was
increased in both adults and children with asthma, irre-
spective of steroid treatment, disease severity or level of
asthma control (Figure 10). Apart from asthma, other dis-
eases such as allergic rhinitis, bronchiectasis, lower and
upper respiratory tract infections, interstitial lung disease
and cystic fibrosis have also shown an increased produc-
tion of eCO [10]. eCO was even found to be elevated in
asymptomatic atopic subjects [35]. These findings sug-
gest that increased eCO level may be an indicator of air-
way inflammation but it does not discriminate between
diseases.
Endogenous CO in the expired air is mainly derived
from the degradation of hemoglobin by HO [10]. Many
mediators present in inflamed airways, including inter-
leukin-1β, tumor necrosis factor-α, interferon-γ and
hydrogen peroxide could induce HO-1 [35]. In vivo chal-
lenge with allergen, but not methacholine, also results in
increased eCO levels, suggesting that an inflammatory
response and not bronchoconstriction per se is necessary
to enhance HO-1 activity and/or expression [36]. HO-1 is
present in alveolar macrophages; however, there is con-
flicting evidence as to whether HO-1 is expressed in the
airway epithelium and whether HO-1 is up-regulated in
asthmatics [9,37,38]. Harju et al [38] showed that HO-1
was up-regulated in the alveolar macrophages of steroid-
free asthmatics, and Horvath et al [9] also found
increased expression of HO-1 in alveolar macrophages in
asthmatics associated with increased exhaled CO. In con-
trast, Lim et al [37] demonstrated that HO-1 was equally
expressed in alveolar macrophages from asthmatics and
healthy subjects. This discrepancy was explained by the
possibility that the airway was already exposed to daily
oxidant stresses such as environment pollutants, and
therefore the expression of HO-1 was probably already
maximal in asthmatics and healthy subjects. Alterna-
tively, the techniques used may not have been sensitive
enough to quantify differences when HO-1 was highly
expressed and enzymic activity was not measured.
The level of eCO in intermittent asthmatics was signifi-
cantly lower than mild + moderate persistent and severe
persistent asthmatics, suggesting that eCO may be corre-
Figure 4 eCO levels in childhood and adult asthma. The WMD of eCO levels between asthmatic children and healthy children is 0.95 ppm (95%CI: 
0.65 to 1.24) using the random effects model. Test for heterogeneity I2 = 59%. The WMD of eCO levels between asthmatic adults and healthy adults 
is 1.49 ppm (95%CI: 0.84 to 2.14) using random effects model. Test for heterogeneity I2 = 73%. SD: standard deviation; IV: inverse variance; CI: confi-
dence interval; WMD: weighted mean difference; eCO: exhaled carbon monoxide.
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cance was found between mild + moderate persistent
asthmatics and severe persistent asthmatics. There was
much greater variability in the 95%CI of WMD for eCO
in severe persistent asthma compared with other groups.
This probably reflects the fact that only 2 studies were
included in this group and the sample size (46 severe per-
sistent asthmatics and 30 healthy subjects) was small,
Figure 5 eCO levels in steroid-free and steroid-treated asthmatics. The WMD of eCO levels between steroid-free asthmatics and healthy subjects 
is 1.39 ppm (95%CI: 0.82 to 1.95) using the random effects model. Test for heterogeneity I2 = 91%. The WMD of eCO levels between steroid-treated 
asthmatics and healthy adults is 0.79 ppm (95%CI: 0.35 to 1.23) using the random effects model. Test for heterogeneity I2 = 84%. SD: standard deviation; 
IV: inverse variance; CI: confidence interval; WMD: weighted mean difference; eCO: exhaled carbon monoxide.
Figure 6 eCO levels in intermittent asthmatics. The WMD of eCO levels between intermittent asthmatics and healthy subjects is 0.31 ppm (95%CI: 
0.16 to 0.46) using the fixed effects model. Test for heterogeneity I2 = 11%. SD: standard deviation; IV: inverse variance; CI confidence interval; WMD: 
weighted mean difference; eCO: exhaled carbon monoxide.
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Figure 7 eCO levels in mild + moderate persistent and severe persistent asthmatics. The WMD of eCO levels between mild + moderate persis-
tent asthmatics and healthy subjects is 0.84 ppm (95%CI: 0.48 to 1.20) using the random effects model. Test for heterogeneity I2 = 62%. The WMD of 
eCO levels between severe persistent asthmatics and healthy subjects is 2.20 ppm (95%CI: 0.29 to 4.10) using the random effects model. Test for het-
erogeneity I2 = 68%. SD: standard deviation; IV: inverse variance; CI: confidence interval; WMD: weighted mean difference; eCO: exhaled carbon mon-
oxide.
Figure 8 eCO levels in different asthma control states. The WMD of eCO levels between controlled + partly controlled asthmatics and healthy 
subjects is 1.20 ppm (95%CI: 0.39 to 2.01) using the random effects model. Test for heterogeneity I2 = 91%. The WMD of eCO levels between uncon-
trolled asthmatics and healthy adults is 2.12 ppm (95%CI: 0.56 to 3.68) using the random effects model. Test for heterogeneity I2 = 95%. SD: standard 
deviation; IV: inverse variance; CI: confidence interval; WMD: weighted mean difference; eCO: exhaled carbon monoxide.
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probably underlies the variability in the uncontrolled
asthma group. Thus, further investigation is needed to
address whether eCO could reflect asthma control status.
Our meta-analysis demonstrated that the eCO level in
steroid-treated asthmatics was not significantly different
from that in steroid-free subjects although the average
level of eCO is increased in steroid-free subjects. The lack
of statistical significance may relate to the small sample
size. In addition, this may possibly also reflect the wide
variability in airway inflammation seen in subjects with
differing degrees of asthma severity and degrees of con-
trol, or the fact that steroids may not affect HO-1 activity
or expression. However, our meta-analysis did demon-
strate a significant effect of a formal steroid intervention
on eCO levels supporting in vitro data showing that ste-
roids are able to directly down-regulate HO-1 promoter
activity and expression [39].
Although steroid treatment could reduce the eCO con-
centrations in asthmatics, the eCO response might be less
sensitive to steroid treatment than that of eNO [26,33].
Recent studies demonstrated that using eNO to guide
treatment did not result in lower exacerbation frequency
as compared to traditional asthma management [40,41].
It is possible that the eNO level is too sensitive to steroid
treatment, and therefore, the underlying inflammation
may still persist despite a significantly decreased eNO
level. Hence, treatment based on the less steroid-sensitive
eCO level, which correlates with asthma severity to some
degree and is reduced after steroid treatment, could be of
benefit.
There are some further limitations to using eCO as an
indicator of airway inflammation. The most obvious one
is that active and passive smoking status can remarkably
affect the eCO level. Both healthy subjects and asthmatic
subjects who were current smokers showed significantly
higher eCO levels than their nonsmoking control subjects
[42,43]. The eCO level of some healthy smoking subjects
could be much higher than the level of nonsmoking
severe persistent asthmatics reported previously [25].
Furthermore, Ece et al [23], demonstrated a significant
relationship between passive smoking and eCO concen-
tration in both healthy and asthmatic children. Thus,
when using eCO levels to assess airway inflammation, the
active and passive smoking status must be taken into con-
sideration.
Another major limitation is the lack of standardization
of eCO measurement. One study included in the meta-
analysis used an infrared detection method and the oth-
ers used an electrochemical method. There was no signif-
icant difference in WMD between asthmatics and healthy
subjects when the study using infrared method was
included (WMD: 1.25 ppm; 95%CI: 0.92 to 1.58; Random
effects model; I2 = 75%) or not (WMD: 1.33 ppm; 95%CI:
0.99 to 1.66; Random effects model; I2 = 74%). Since the
Figure 9 eCO levels before and after steroid treatment. The WMD of eCO levels before and after steroid treatment is 1.98 ppm (95%CI: 0.53 to 
3.43) using the random effects model. Test for heterogeneity I2 = 94%. SD: standard deviation; IV: inverse variance; CI: confidence interval; WMD: 
weighted mean difference; eCO: exhaled carbon monoxide.
Figure 10 eCO WMD (95%CI) between different asthma groups 
and healthy subjects. There were no significant differences in eCO 
levels between steroid-free and steroid-treated asthmatics, mild + 
moderate persistent and severe persistent asthma, controlled + partly 
controlled and uncontrolled asthma. However, the eCO level of inter-
mittent asthma was significantly lower than mild + moderate persis-
tent asthma. CI: confidence interval; WMD: weighted mean difference; 
eCO: exhaled carbon monoxide; Њ: mean of WMD between asthmat-
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analysis are similar to those reported previously [42] we
did not exclude studies due to their different measure-
ments.
Conclusions
eCO is elevated in non-smoking asthmatics and corre-
lates with disease severity to some extent. Whether eCO
reflects asthma control requires further investigation.
Although eCO could not distinguish steroid-treated from
steroid-free patients in a cross-sectional analysis, formal
steroid treatment significantly reduced eCO levels. eCO
might be a potentially useful non-invasive biomarker of
airway inflammation and oxidative stress in nonsmoking
asthmatics but further work is needed in this area.
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